Logo image of ADOC.PA

ADOCIA SAS (ADOC.PA) Stock Fundamental Analysis

EPA:ADOC - Euronext Paris - Matif - FR0011184241 - Common Stock - Currency: EUR

6.7  +0.13 (+1.98%)

Fundamental Rating

2

Overall ADOC gets a fundamental rating of 2 out of 10. We evaluated ADOC against 73 industry peers in the Biotechnology industry. ADOC may be in some trouble as it scores bad on both profitability and health. ADOC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADOC has reported negative net income.
ADOC had a negative operating cash flow in the past year.
ADOC had negative earnings in each of the past 5 years.
ADOC had a negative operating cash flow in each of the past 5 years.
ADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

With a Return On Assets value of -34.50%, ADOC perfoms like the industry average, outperforming 46.58% of the companies in the same industry.
Industry RankSector Rank
ROA -34.5%
ROE N/A
ROIC N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADOC.PA Yearly ROA, ROE, ROICADOC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

ADOC's Gross Margin of 87.98% is amongst the best of the industry. ADOC outperforms 87.67% of its industry peers.
ADOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADOC.PA Yearly Profit, Operating, Gross MarginsADOC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADOC has been increased compared to 1 year ago.
ADOC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADOC has an improved debt to assets ratio.
ADOC.PA Yearly Shares OutstandingADOC.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ADOC.PA Yearly Total Debt VS Total AssetsADOC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of 0.11, we must say that ADOC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ADOC (0.11) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.11
ROIC/WACCN/A
WACC7.49%
ADOC.PA Yearly LT Debt VS Equity VS FCFADOC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.08 indicates that ADOC should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.08, ADOC is doing worse than 72.60% of the companies in the same industry.
ADOC has a Quick Ratio of 1.07. This is a normal value and indicates that ADOC is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.07, ADOC is doing worse than 67.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.07
ADOC.PA Yearly Current Assets VS Current LiabilitesADOC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

ADOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.43%, which is quite impressive.
ADOC shows a strong growth in Revenue. In the last year, the Revenue has grown by 333.49%.
Measured over the past years, ADOC shows a very strong growth in Revenue. The Revenue has been growing by 34.18% on average per year.
EPS 1Y (TTM)66.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.28%
Revenue 1Y (TTM)333.49%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%1682.03%

3.2 Future

The Earnings Per Share is expected to grow by 2.80% on average over the next years.
The Revenue is expected to grow by 17.84% on average over the next years. This is quite good.
EPS Next Y-26.35%
EPS Next 2Y-22.56%
EPS Next 3Y-55.87%
EPS Next 5Y2.8%
Revenue Next Year-53.12%
Revenue Next 2Y-30.63%
Revenue Next 3Y-42.95%
Revenue Next 5Y17.84%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADOC.PA Yearly Revenue VS EstimatesADOC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
ADOC.PA Yearly EPS VS EstimatesADOC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ADOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 1.51, which indicates a rather cheap valuation of ADOC.
Based on the Price/Forward Earnings ratio, ADOC is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.28, ADOC is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.51
ADOC.PA Price Earnings VS Forward Price EarningsADOC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADOC.PA Per share dataADOC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

A cheap valuation may be justified as ADOC's earnings are expected to decrease with -55.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.56%
EPS Next 3Y-55.87%

More info and screens

0

5. Dividend

5.1 Amount

ADOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADOCIA SAS

EPA:ADOC (8/7/2025, 5:29:57 PM)

6.7

+0.13 (+1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-23 2025-07-23
Earnings (Next)10-15 2025-10-15
Inst Owners14.87%
Inst Owner ChangeN/A
Ins Owners9.82%
Ins Owner ChangeN/A
Market Cap122.48M
Analysts85.71
Price Target12.24 (82.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)31.15%
PT rev (3m)31.15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-42.31%
Revenue NY rev (3m)-42.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.51
P/S 13.14
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)4.45
Fwd EY66.38%
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.51
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.98%
FCFM N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.02%
Cap/Sales 2.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.07
Altman-Z 0.11
F-Score5
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)32.19%
Cap/Depr(5y)28.97%
Cap/Sales(3y)3.68%
Cap/Sales(5y)12.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.28%
EPS Next Y-26.35%
EPS Next 2Y-22.56%
EPS Next 3Y-55.87%
EPS Next 5Y2.8%
Revenue 1Y (TTM)333.49%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%1682.03%
Revenue Next Year-53.12%
Revenue Next 2Y-30.63%
Revenue Next 3Y-42.95%
Revenue Next 5Y17.84%
EBIT growth 1Y48.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-210.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-215.33%
OCF growth 3YN/A
OCF growth 5YN/A